Minimally invasive surgery to treat embryonal tumors of childhood.
Hannah M PhelpsHarold N LovvornPublished in: Cancer metastasis reviews (2020)
Minimally invasive surgery (MIS) to resect primary and metastatic pediatric embryonal tumors offers the potential for reduced postoperative morbidity with smaller wounds, less pain, fewer surgical site infections, decreased blood loss, shorter hospital stays, and less disruption to treatment regimens. However, significant controversy surrounds the question of whether a high-fidelity oncologic resection of childhood embryonal tumors with gross total resection, negative margins, and appropriate lymph node sampling can be achieved through MIS. This review outlines the diverse applications of MIS to treat definitively pediatric embryonal malignancies, including this approach to metastatic deposits. It outlines specific patient populations and presentations that may be particularly amenable to the minimally invasive approach. This work further summarizes the current evidence supporting the efficacy of MIS to accomplish a definitive, oncologic resection without compromising relapse-free or overall survival. Finally, the review offers technical considerations to consider in order to achieve a safe and complete resection.
Keyphrases
- lymph node
- minimally invasive
- squamous cell carcinoma
- small cell lung cancer
- healthcare
- robot assisted
- rectal cancer
- childhood cancer
- case report
- chronic pain
- radical prostatectomy
- prostate cancer
- neoadjuvant chemotherapy
- free survival
- emergency department
- locally advanced
- climate change
- early life
- neuropathic pain
- early stage
- radiation therapy
- combination therapy
- smoking cessation
- wound healing
- replacement therapy